Concepedia

Matthias Nettekoven

MN

31

Publications

911

Citations

20

H-Index

1995

Active since

Affiliations

Roche (Switzerland)(Current)

University of L'Aquila

Dalhousie University

European Brain Research Institute

Technical University of Munich

Matthias Nettekoven is an author at Roche (Switzerland) specializing in pharmacology, medicine, and drug discovery.

Top concepts

PharmacologyMedicineBiochemistryDrug DiscoveryNatural SciencesMedicinal ChemistryPharmacotherapyChemistryOrganic ChemistryEngineering

Publications per year

1995–2024

31

Publications

31

Biochemical and behavioural characterization of EMPA, a novel high‐affinity, selective antagonist for the OX<sub>2</sub> receptor

P. Malherbe, Edilio Borroni, Luca Gobbi et al. · British Journal of Pharmacology · 2009 · 92 citations · Full text

Ligand-Based Combinatorial Design of Selective Purinergic Receptor (A<sub>2A</sub>) Antagonists Using Self-Organizing Maps

Gisbert Schneider, Matthias Nettekoven · Journal of Combinatorial Chemistry · 2003 · 69 citations

Lead Generation - Enhancing the Success of Drug Discovery by Investing in the Hit to Lead Process

Alexander Alanine, Matthias Nettekoven, Edward Roberts et al. · Combinatorial Chemistry & High Throughput Screening · 2003 · 57 citations

Lead Conversion, Pharmaceutical Research, Hit Identification +18

Novel Triazolopyrimidine‐Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases

Matthias Nettekoven, Jean‐Michel Adam, Stefanie Bendels et al. · ChemMedChem · 2015 · 56 citations

Renal Inflammation, Pharmacotherapy, Cannabinoid Pharmacology +20

Benzodioxoles: Novel Cannabinoid-1 Receptor Inverse Agonists for the Treatment of Obesity

Leo Alig, Jochem Alsenz, Mirjana Andjelković et al. · Journal of Medicinal Chemistry · 2008 · 42 citations · Full text

Rows per page

1–5 of 31